TrialDiabetes, obesity & metabolism2026

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).

Carel W le Roux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.